clinical trial · NCT02230553
Lapatinib Plus Trametinib in KRAS Mutant NSCLC
The Netherlands Cancer Institute·phase2·completed·n = 35
Colorectal CancerLapatinibtrametinib
brief summary
This is an open-label phase I/II multi-center study consisting of two parts. Part A of this study is designed to identify the recommended phase 2 dose (RP2D) of lapatinib combined with trametinib in patients with metastatic KRASm and PIK3CA wild-type (PIK3CAwt) non-small cell lung cancer (NSCLC). Part B is designed to perform a randomized comparison of the lapatinib-trametinib combination versus standard of care therapy in patients with metastatic KRASm/PIK3CAwt NSCLC.
started
Oct 7, 2014
primary completion
Jul 29, 2019
completion
Aug 6, 2019
last updated
Jul 8, 2025
official title
Phase I/II Study With Lapatinib Plus Trametinib in Patients With Metastatic KRAS Mutant Non-small Cell Lung Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol